215 related articles for article (PubMed ID: 33168658)
1. Oncolytic Reovirus (pelareorep) Induces Autophagy in KRAS-mutated Colorectal Cancer.
Jiffry J; Thavornwatanayong T; Rao D; Fogel EJ; Saytoo D; Nahata R; Guzik H; Chaudhary I; Augustine T; Goel S; Maitra R
Clin Cancer Res; 2021 Feb; 27(3):865-876. PubMed ID: 33168658
[TBL] [Abstract][Full Text] [Related]
2. Immune characterization of metastatic colorectal cancer patients post reovirus administration.
Parakrama R; Fogel E; Chandy C; Augustine T; Coffey M; Tesfa L; Goel S; Maitra R
BMC Cancer; 2020 Jun; 20(1):569. PubMed ID: 32552875
[TBL] [Abstract][Full Text] [Related]
3. Oncolytic reovirus preferentially induces apoptosis in KRAS mutant colorectal cancer cells, and synergizes with irinotecan.
Maitra R; Seetharam R; Tesfa L; Augustine TA; Klampfer L; Coffey MC; Mariadason JM; Goel S
Oncotarget; 2014 May; 5(9):2807-19. PubMed ID: 24798549
[TBL] [Abstract][Full Text] [Related]
4. Elucidation of Pelareorep Pharmacodynamics in A Phase I Trial in Patients with
Goel S; Ocean AJ; Parakrama RY; Ghalib MH; Chaudhary I; Shah U; Viswanathan S; Kharkwal H; Coffey M; Maitra R
Mol Cancer Ther; 2020 May; 19(5):1148-1156. PubMed ID: 32156785
[No Abstract] [Full Text] [Related]
5. A Randomized Phase II Study of FOLFOX6/Bevacizumab With or Without Pelareorep in Patients With Metastatic Colorectal Cancer: IND.210, a Canadian Cancer Trials Group Trial.
Jonker DJ; Tang PA; Kennecke H; Welch SA; Cripps MC; Asmis T; Chalchal H; Tomiak A; Lim H; Ko YJ; Chen EX; Alcindor T; Goffin JR; Korpanty GJ; Feilotter H; Tsao MS; Theis A; Tu D; Seymour L
Clin Colorectal Cancer; 2018 Sep; 17(3):231-239.e7. PubMed ID: 29653857
[TBL] [Abstract][Full Text] [Related]
6. Predictive and prognostic implications of 4E-BP1, Beclin-1, and LC3 for cetuximab treatment combined with chemotherapy in advanced colorectal cancer with wild-type KRAS: Analysis from real-world data.
Guo GF; Wang YX; Zhang YJ; Chen XX; Lu JB; Wang HH; Jiang C; Qiu HQ; Xia LP
World J Gastroenterol; 2019 Apr; 25(15):1840-1853. PubMed ID: 31057298
[TBL] [Abstract][Full Text] [Related]
7. Pembrolizumab in Combination with the Oncolytic Virus Pelareorep and Chemotherapy in Patients with Advanced Pancreatic Adenocarcinoma: A Phase Ib Study.
Mahalingam D; Wilkinson GA; Eng KH; Fields P; Raber P; Moseley JL; Cheetham K; Coffey M; Nuovo G; Kalinski P; Zhang B; Arora SP; Fountzilas C
Clin Cancer Res; 2020 Jan; 26(1):71-81. PubMed ID: 31694832
[TBL] [Abstract][Full Text] [Related]
8. Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer.
Peeters M; Price TJ; Cervantes A; Sobrero AF; Ducreux M; Hotko Y; André T; Chan E; Lordick F; Punt CJ; Strickland AH; Wilson G; Ciuleanu TE; Roman L; Van Cutsem E; Tzekova V; Collins S; Oliner KS; Rong A; Gansert J
J Clin Oncol; 2010 Nov; 28(31):4706-13. PubMed ID: 20921462
[TBL] [Abstract][Full Text] [Related]
9. Detection of KRAS oncogene in peripheral blood as a predictor of the response to cetuximab plus chemotherapy in patients with metastatic colorectal cancer.
Yen LC; Yeh YS; Chen CW; Wang HM; Tsai HL; Lu CY; Chang YT; Chu KS; Lin SR; Wang JY
Clin Cancer Res; 2009 Jul; 15(13):4508-13. PubMed ID: 19549774
[TBL] [Abstract][Full Text] [Related]
10. KRAS and BRAF mutations in advanced colorectal cancer are associated with poor prognosis but do not preclude benefit from oxaliplatin or irinotecan: results from the MRC FOCUS trial.
Richman SD; Seymour MT; Chambers P; Elliott F; Daly CL; Meade AM; Taylor G; Barrett JH; Quirke P
J Clin Oncol; 2009 Dec; 27(35):5931-7. PubMed ID: 19884549
[TBL] [Abstract][Full Text] [Related]
11. Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study.
Douillard JY; Siena S; Cassidy J; Tabernero J; Burkes R; Barugel M; Humblet Y; Bodoky G; Cunningham D; Jassem J; Rivera F; Kocákova I; Ruff P; Błasińska-Morawiec M; Šmakal M; Canon JL; Rother M; Oliner KS; Wolf M; Gansert J
J Clin Oncol; 2010 Nov; 28(31):4697-705. PubMed ID: 20921465
[TBL] [Abstract][Full Text] [Related]
12. Toll like receptor 3 as an immunotherapeutic target for KRAS mutated colorectal cancer.
Maitra R; Augustine T; Dayan Y; Chandy C; Coffey M; Goel S
Oncotarget; 2017 May; 8(21):35138-35153. PubMed ID: 28422714
[TBL] [Abstract][Full Text] [Related]
13. Canadian Cancer Trials Group (CCTG) IND211: A randomized trial of pelareorep (Reolysin) in patients with previously treated advanced or metastatic non-small cell lung cancer receiving standard salvage therapy.
Bradbury PA; Morris DG; Nicholas G; Tu D; Tehfe M; Goffin JR; Shepherd FA; Gregg RW; Rothenstein J; Lee C; Kuruvilla S; Keith BD; Torri V; Blais N; Hao D; Korpanty GJ; Goss G; Melosky BL; Mates M; Leighl N; Ayoub JP; Sederias J; Feilotter H; Seymour L; Laurie SA
Lung Cancer; 2018 Jun; 120():142-148. PubMed ID: 29748010
[TBL] [Abstract][Full Text] [Related]
14. Comparison of KRAS genotype: therascreen assay vs. LNA-mediated qPCR clamping assay.
Chang SC; Denne J; Zhao L; Horak C; Green G; Khambata-Ford S; Bray C; Celik I; Van Cutsem E; Harbison C
Clin Colorectal Cancer; 2013 Sep; 12(3):195-203.e2. PubMed ID: 23978462
[TBL] [Abstract][Full Text] [Related]
15. Efficacy, Tolerability, and Biomarker Analyses of Once-Every-2-Weeks Cetuximab Plus First-Line FOLFOX or FOLFIRI in Patients With KRAS or All RAS Wild-Type Metastatic Colorectal Cancer: The Phase 2 APEC Study.
Cheng AL; Cornelio G; Shen L; Price T; Yang TS; Chung IJ; Dai GH; Lin JK; Sharma A; Yeh KH; Ma B; Zaatar A; Guan Z; Masood N; Srimuninnimit V; Yau T; Gibbs P; Wang X; Doval DC; Oh ST; Shim BY; Gorospe C; Wang HM; Sirachainan E; Hill A; Suh KW; Beier F; Chatterjee S; Lim R
Clin Colorectal Cancer; 2017 Jun; 16(2):e73-e88. PubMed ID: 27780749
[TBL] [Abstract][Full Text] [Related]
16. The efficacy and safety of panitumumab administered concomitantly with FOLFIRI or Irinotecan in second-line therapy for metastatic colorectal cancer: the secondary analysis from STEPP (Skin Toxicity Evaluation Protocol With Panitumumab) by KRAS status.
Mitchell EP; Piperdi B; Lacouture ME; Shearer H; Iannotti N; Pillai MV; Xu F; Yassine M
Clin Colorectal Cancer; 2011 Dec; 10(4):333-9. PubMed ID: 22000810
[TBL] [Abstract][Full Text] [Related]
17. Quality of Life Analysis in Patients With RAS Wild-Type Metastatic Colorectal Cancer Treated With First-Line Cetuximab Plus Chemotherapy.
Yamaguchi K; Ando M; Ooki A; Beier F; Guenther S; von Hohnhorst P; Van Cutsem E
Clin Colorectal Cancer; 2017 Jun; 16(2):e29-e37. PubMed ID: 28081962
[TBL] [Abstract][Full Text] [Related]
18. Metastatic colorectal cancer treatment patterns according to kirsten rat sarcoma viral oncogene homolog genotype in U.S. Community-based oncology practices.
Landsman-Blumberg PB; Carter GC; Johnson BH; Sedgley R; Nicol SJ; Li L; Shankaran V
Clin Colorectal Cancer; 2014 Sep; 13(3):178-84. PubMed ID: 25065655
[TBL] [Abstract][Full Text] [Related]
19. An open-label, single-arm, phase 2 trial of panitumumab plus FOLFIRI as second-line therapy in patients with metastatic colorectal cancer.
Cohn AL; Shumaker GC; Khandelwal P; Smith DA; Neubauer MA; Mehta N; Richards D; Watkins DL; Zhang K; Yassine MR
Clin Colorectal Cancer; 2011 Sep; 10(3):171-7. PubMed ID: 21855038
[TBL] [Abstract][Full Text] [Related]
20. Apremilast Induces Apoptosis of Human Colorectal Cancer Cells with Mutant
Nishi K; Luo H; Ishikura S; Doi K; Iwaihara Y; Wills L; Baillie GS; Sakata T; Shirasawa S; Tsunoda T
Anticancer Res; 2017 Jul; 37(7):3833-3839. PubMed ID: 28668883
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
